<DOC>
	<DOCNO>NCT01792284</DOCNO>
	<brief_summary>The primary purpose participation study compare safety efficacy different dose schedule LY2605541 different dose schedule LY2605541 affect Hemoglobin A1c ( HbA1c ) . Participants treat 36 week LY2605541 ( one 12-week Lead-in period two 12-week Randomization period ) 42 week total study enrollment ( 10 day screen period 4 week Follow-up period ) .</brief_summary>
	<brief_title>A Study LY2605541 Participants With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Type 1 diabetes mellitus least one year Have HbA1c value &lt; 9.0 % Have Body Mass Index ( BMI ) â‰¤35.0 kilogram per square meter ( kg/m^2 ) Currently use basal/ bolus insulin Women childbearing potential breastfeeding must use method prevent pregnancy Have excessive insulin resistance Taking medication insulin diabetes High triglyceride Have 1 episode severe hypoglycemia ( define require assistance due neurologically disable hypoglycemia determine investigator ) within 6 month prior entry study Have 2 emergency room visit hospitalization due poor glucose control ( hyperglycemia diabetic ketoacidosis ) past 6 month Have cardiac disease functional status New York Heart Association ( NYHA ) Class III IV ( per NYHA Cardiac Disease Classification ) Impaired renal function Impaired liver function Have blood transfusion severe blood loss within 3 month prior screen know hemoglobinopathy , hemolytic anemia , sickle cell anemia , traits hemoglobin abnormality know interfere HbA1c measurement Cancer , recent cancer , risk cancer Have know hypersensitivity allergy study insulins excipients Chronic systemic glucocorticoid use Clinically significant diabetic autonomic neuropathy Have irregular sleep/wake cycle Have treat drug within last 30 day receive regulatory approval time study entry Prior study participation Are use use niacin preparation lipidlowering medication and/or bile acid sequestrants within 90 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>